IBD Frequently Observed in Early Axial Spondyloarthritis
Inflammatory bowel disease occurs with an incidence of 1/100 patient-years in early spondyloarthritis.
Spondyloarthritis
Guselkumab vs Secukinumab Treatment Outcomes in Self-Reported PsA
In the subset of patients with self-reported psoriatic arthritis, guselkumab demonstrated better maintenance of response and higher efficacy compared with secukinumab in the treatment of moderate to severe plaque psoriasis.
Modified New York and ASAS Criteria Interchangeable in AxSpA With Radiographic Sacroiliitis
Findings support the interchangeable use of the terms radiographic axial spondyloarthritis and ankylosing spondylitis.
Tildrakizumab Safe, Efficacious for Treating Active Psoriatic Arthritis
A phase 2b study showed that tildrakizumab was significantly more efficacious than placebo in treatment of joint and skin manifestations of psoriatic arthritis by week 24.
Ixekizumab May Be Superior to Adalimumab in bDMARD-Naïve Patients With PsA
Open-label head-to-head trial compared efficacy and safety of ixekizumab with adalimumab in patients with psoriatic arthritis naive to biologic disease-modifying anti-rheumatic drugs.
Secukinumab Improves Axial Manifestations in Psoriatic Arthritis
MAXIMISE is an ongoing study evaluating the efficacy and safety of secukinumab 300 mg or 150mg in managing axial manifestations in patients with psoriatic arthritis.
Etanercept-Based Treatments Superior to Methotrexate Monotherapy in PsA
Etanercept monotherapy and combination therapy with etanercept and methotrexate showed greater efficacy than methotrexate monotherapy in patients with psoriatic arthritis.
Impaired Lateral Spinal Flexion in Early-Stage AS Linked to Worse Prognosis
The use of age- and height-adjusted reference intervals could significantly improve spinal mobility assessment during the course of ankylosing spondylitis disease.
Simplifying, Improving the Bath Ankylosing Spondylitis Disease Activity Index
Improvements to the traditional Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were necessary to meet the requirements of Rasch Measurement Theory resulting in the identification of a modified 5-item BASDAI measure that demonstrated good precision and internal validity.
CV Events, Lipid Level Changes Following Tofacitinib Exposure in PsA
Investigators assessed cardiovascular risk factors and major adverse cardiovascular events in patients with active psoriatic arthritis who received tofacitinib 5 or 10 mg twice daily plus conventional synthetic disease-modifying antirheumatic drugs.
Next post in Psoriatic Arthritis
